Evidence map›Paper›PMID 18559643›Full record

ArticleAntimicrobial agents and chemotherapy2008

Inhibition of OXA-1 beta-lactamase by penems.

Christopher R Bethel, Anne M Distler, Mark W Ruszczycky, Marianne P Carey, Paul R Carey, Andrea M Hujer, Magda Taracila, Marion S Helfand, Jodi M Thomson, Matthew Kalp and 7 more

Open access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 33 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Penicillin sulfone inhibitors of class D beta-lactamases.Antimicrobial agents and chemotherapy · 2010
    Article
  16. Article
  17. Article
  18. Three decades of beta-lactamase inhibitors.Clinical microbiology reviews · 2010
    Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 1 country.

Christopher R BethelLouis Stokes Cleveland Department of Veterans Affairs Medical Center, Research Service, Cleveland, Ohio 44106, USA.
Anne M Distler
Mark W Ruszczycky
Marianne P Carey
Paul R Carey
Andrea M Hujer
Magda Taracila
Marion S Helfand
Jodi M Thomson
Matthew Kalp
Vernon E Anderson
David A Leonard
Kristine M Hujer
Takao Abe
Aranapakam M Venkatesan
Tarek S Mansour
Robert A Bonomo
Louis Stokes Cleveland VA Medical Center · USCase Western Reserve University · USPearl River Community College · USUniversity School · USGrand Valley State University · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007250 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, ALEX YEE-CHEN · 1985 to 2023
$33.4M
NIGMS NIH HHS T32 GM007250NIGMS NIH HHS T32 GM07250PHS HHS 1R01 A1063517-01
6 · The paper itself

Abstract

The partnering of a beta-lactam with a beta-lactamase inhibitor is a highly effective strategy that can be used to combat bacterial resistance to beta-lactam antibiotics mediated by serine beta-lactamases (EC 3.2.5.6). To this end, we tested two novel penem inhibitors against OXA-1, a class D beta-lactamase that is resistant to inactivation by tazobactam. The K(i) of each penem inhibitor for OXA-1 was in the nM range (K(i) of penem 1, 45 +/- 8 nM; K(i) of penem 2, 12 +/- 2 nM). The first-order rate constant for enzyme and inhibitor complex inactivation of penems 1 and 2 for OXA-1 beta-lactamase were 0.13 +/- 0.01 s(-1) and 0.11 +/- 0.01 s(-1), respectively. By using an inhibitor-to-enzyme ratio of 1:1, 100% inactivation was achieved in <or=900 s and the recovery of OXA-1 beta-lactamase activity was not detected at 24 h. Covalent adducts of penems 1 and 2 (changes in molecular masses, +306 +/- 3 and +321 +/- 3 Da, respectively) were identified by electrospray ionization mass spectrometry (ESI-MS). After tryptic digestion of OXA-1 inactivated by penems 1 and 2, ESI-MS and matrix-assisted laser desorption ionization-time-of-flight MS identified the adducts of 306 +/- 3 and 321 +/- 3 Da attached to the peptide containing the active-site Ser67. The base hydrolysis of penem 2, monitored by serial (1)H nuclear magnetic resonance analysis, suggested that penem 2 formed a linear imine species that underwent 7-endo-trig cyclization to ultimately form a cyclic enamine, the 1,4-thiazepine derivative. Susceptibility testing demonstrated that the penem inhibitors at 4 mg/liter effectively restored susceptibility to piperacillin. Penem beta-lactamase inhibitors which demonstrate high affinities and which form long-lived acyl intermediates may prove to be extremely useful against the broad range of inhibitor-resistant serine beta-lactamases present in gram-negative bacteria.

Indexed as

beta-Lactamase InhibitorsAnti-Bacterial Agentsbeta-LactamasesBridged Bicyclo CompoundsEnzyme InhibitorsEscherichia coliHeterocyclic CompoundsKineticsMicrobial Sensitivity TestsPenicillanic AcidPiperacillinStructure-Activity RelationshipTazobactamAnti-Bacterial Agentsbeta-Lactamase Inhibitorsbeta-lactamase OXA-2beta-LactamasesBridged Bicyclo CompoundsEnzyme InhibitorsHeterocyclic CompoundsPenicillanic AcidPiperacillinTazobactam

Identifiers

PMID18559643
PMCPMC2533510
OpenAlexW1937143154

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.